Yoshida Yilin, Cheng Xi, Shao Hui, Fonseca Vivian A, Shi Lizheng
Section of Endocrinology, Department of Medicine, School of Medicine, Tulane University, New Orleans, LA, USA.
Department of Health Services and Policy Management, School of Public Health, University of South Carolina, Columbia, SC, USA.
Curr Diab Rep. 2020 Mar 12;20(4):12. doi: 10.1007/s11892-020-1292-5.
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are the most recently approved class of drugs (since 2012) for type 2 diabetes mellitus (T2DM), but their economic merits have yet been fully confirmed. The objective of this review was to evaluate the most updated evidence that examined the cost-effectiveness of SGLT2i for T2DM.
We systematically searched Medline (PubMed), EMBASE, and Web of Science for eligible articles from January 1, 2011, to October 31, 2019, using combinations of search words. A supplementary search using reference lists of eligible articles and other review articles was also performed. A multistage screening process was carried out with duplicates removal, abstract screening, and full-text reading to confirm eligibility. Two reviewers independently screened the eligible articles and assessed reporting quality using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. A total of 24 studies were included in the final review. All studies showed good quality according to the CHEERS checklist (scored 21-24). Seven studies compared SGLT2i vs. dipeptidyl peptidase-4 inhibitors (DPP-4i), 3 studies compared SGLT2i vs. sulfonylureas (SU), 3 compared SGLT2i vs. glucagon-like peptide-1 receptor agonist (GLP-1 RA), 2 compared SGLT2i vs. SGLT2i, 3 compared SGLT2i vs. other antidiabetic therapies including thiazolidinediones (TZD), alpha-glucosidase inhibitors (AGI) or insulin, and 5 compared SGLT2i vs. standard care/metformin. Most studies concluded SGLT2i was cost-effective relative to its comparator except GLP-1 RA, where two studies suggested GLP-1 RA was the favorable treatment option relative to SGLT2i. The literature demonstrated that SGLT2i may be cost-effective compared to many antidiabetic therapies including DPP-4i, SU, TZD, AGI, insulin, and standard care .
钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）是最近（自2012年起）被批准用于2型糖尿病（T2DM）治疗的一类药物，但其经济优势尚未得到充分证实。本综述的目的是评估有关SGLT2i治疗T2DM成本效益的最新证据。
我们使用检索词组合，在Medline（PubMed）、EMBASE和Web of Science数据库中系统检索了2011年1月1日至2019年10月31日期间的符合条件的文章。还使用符合条件文章的参考文献列表和其他综述文章进行了补充检索。通过去除重复文献、摘要筛选和全文阅读的多阶段筛选过程来确认入选资格。两名评审员独立筛选符合条件的文章，并使用综合健康经济评估报告标准（CHEERS）清单评估报告质量。最终综述共纳入24项研究。根据CHEERS清单，所有研究质量良好（得分21 - 24分）。7项研究比较了SGLT2i与二肽基肽酶-4抑制剂（DPP-4i），3项研究比较了SGLT2i与磺脲类药物（SU），3项研究比较了SGLT2i与胰高血糖素样肽-1受体激动剂（GLP-1 RA），2项研究比较了SGLT2i与SGLT2i，3项研究比较了SGLT2i与其他抗糖尿病疗法，包括噻唑烷二酮类药物（TZD）、α-葡萄糖苷酶抑制剂（AGI）或胰岛素，5项研究比较了SGLT2i与标准治疗/二甲双胍。除GLP-1 RA外，大多数研究得出结论，SGLT2i相对于其对照药物具有成本效益，有两项研究表明相对于SGLT2i，GLP-1 RA是更有利的治疗选择。文献表明，与许多抗糖尿病疗法相比，包括DPP-4i、SU、TZD、AGI、胰岛素和标准治疗，SGLT2i可能具有成本效益。
